Anticoagulant therapy of thromboembolic disease during pregnancy

W H Wehrmacher; R L Karlman; P Scanlon; H L Messmore Jr

Anticoagulant therapy of thromboembolic disease during pregnancy

Compr Ther. 1998 Jun-Jul;24(6-7):289-94.

Authors

W H Wehrmacher¹, R L Karlman, P Scanlon, H L Messmore Jr

Affiliation

¹ Department of Physiology, Loyola University Chicago, Stritch School of Medicine, Maywood, IL 60153, USA.

PMID: 9669092

Abstract

There is growing interest in low molecular weight heparin for the management of thromboembolic disease in pregnancy. Greater understanding of the risk of thromboembolic disease versus the risk of various management practices is urgently needed to reduce maternal mortality and embryopathy in the fetus.

Publication types

Review

MeSH terms

Adult
Anticoagulants / therapeutic use*
Female
Heparin / therapeutic use
Heparin, Low-Molecular-Weight / therapeutic use
Humans
Pregnancy
Pregnancy Complications, Hematologic / drug therapy*
Pregnancy Complications, Hematologic / epidemiology
Risk Factors
Thrombosis / drug therapy*
Thrombosis / epidemiology
Warfarin / therapeutic use

Substances

Anticoagulants
Heparin, Low-Molecular-Weight
Warfarin
Heparin